Intended for healthcare professionals

Clinical Review

Diagnosis, investigation, and management of deep vein thrombosis

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1180 (Published 29 May 2003) Cite this as: BMJ 2003;326:1180

Idiopathic deep vein thrombosis and the duration of low-intensity warfarin

Thank you for your comments about the use of low intensity warfarin.

The two studies ELATE and PREVENT are of great clinical importance
and it is likely that many patients in the future will be treated with a
low-intensity warfarin regimen.

The PREVENT trial was not published until April 2003 and it was too
late to have included in our paper. As we were confined to 2000 words I
did not discuss the possibility of using low intensity warfarin.

I am grateful that you have highlighted these two recent studies.

Competing interests:  
I have been reimbursed by Pharmacia, the manufacturers of Fragmin, for attending a conference

Competing interests: No competing interests

11 June 2003
Clive Tovey
Consultant A&E
Prince Charles Hospital, Merthyr Tydfil, Mid Glamorgan, CF47 9DT